Bottom line
How much do XLV and FACDX overlap?
45% of their top holdings overlap by weight. 10 securities appear in both funds' top 25, making up 58.4% of XLV's assets and 38.1% of FACDX's. They share a meaningful core but differ in the rest of the portfolio.
FACDX holds far more positions (154 vs 65), so it is broader beyond the top names.
Updated Nov 22, 2026
Overlap at a glance
Holdings XLV and FACDX have in common
| Holding | % of XLV | % of FACDX | Overlap |
|---|---|---|---|
| Eli Lilly & Co | 16.51% | 7.66% | 7.66% |
| Johnson & Johnson | 10.64% | 3.78% | 3.78% |
| AbbVie Inc | 7.74% | 3.62% | 3.62% |
| UnitedHealth Group Inc | 6.57% | 4.17% | 4.17% |
| Merck & Co Inc | 5.52% | 2.09% | 2.09% |
| Thermo Fisher Scientific Inc | 3.24% | 6.31% | 3.24% |
| Gilead Sciences Inc | 2.73% | 1.25% | 1.25% |
| CVS Health Corp | 2.30% | 1.29% | 1.29% |
| Danaher Corp | 2.09% | 6.75% | 2.09% |
| Boston Scientific Corp | 1.10% | 1.23% | 1.10% |
Source: SEC Form N-PORT (periods Jun 30, 2026 / Jul 31, 2026)
Free weekly newsletter
The Fund Letter
Get fee cuts and hikes, fund closures and mergers, and one plain-English idea to make your portfolio cheaper — every week.
Free. Unsubscribe anytime. We never sell your email.
What each fund holds that the other doesn't
Top-25 holdings that appear in only one of the two funds' top 25.
Only in XLV
- Amgen Inc — 3.40%
- Abbott Laboratories — 2.75%
- Intuitive Surgical Inc — 2.45%
- Pfizer Inc — 2.39%
- Vertex Pharmaceuticals Inc — 2.19%
- Bristol-Myers Squibb Co — 2.05%
- Stryker Corp — 1.89%
- Medtronic PLC — 1.75%
- McKesson Corp — 1.58%
- Elevance Health Inc — 1.46%
- Cigna Group/The — 1.27%
- Regeneron Pharmaceuticals Inc — 1.08%
- HCA Healthcare Inc — 1.05%
- Cardinal Health Inc — 0.97%
- Cencora Inc — 0.96%
Only in FACDX
- Fidelity Revere Street Trust — 2.54%
- Argenx Se — 2.09%
- West Pharmaceutical Svcs Inc — 2.06%
- Ascendis Pharma A/s — 1.95%
- Alnylam Pharmaceuticals Inc — 1.78%
- Agilent Technologies Inc — 1.75%
- Viatris Inc — 1.67%
- Natera Inc — 1.65%
- Guardant Health Inc — 1.48%
- 10x Genomics Inc — 1.45%
- Revolution Medicines Inc — 1.44%
- Waters Corp — 1.43%
- Oruka Therapeutics Inc — 1.32%
- Ucb Sa — 1.32%
- Repligen Corp — 1.22%
Asset mix
| Asset type | XLV | FACDX |
|---|---|---|
| Stocks | 99.7% | 97.7% |
| Cash & short-term funds | 0.3% | 2.8% |
| Preferred stock | — | 2.1% |
| Bonds | — | 0.2% |
Source: SEC Form N-PORT (periods Jun 30, 2026 / Jul 31, 2026)
Country mix
| Country | XLV | FACDX |
|---|---|---|
| US | 97.9% | 88.0% |
| NL | — | 2.9% |
| GB | — | 2.6% |
| IE | 2.1% | 1.0% |
| DK | — | 2.0% |
| BE | — | 1.3% |
| KY | — | 1.3% |
| BM | — | 1.0% |
Source: SEC Form N-PORT (periods Jun 30, 2026 / Jul 31, 2026)
Check another pair
FAQ
How much do XLV and FACDX overlap?
What stocks do XLV and FACDX have in common?
Should I own both XLV and FACDX?
Which holds more stocks, XLV or FACDX?
Overlap is computed from each fund's top 25 holdings in its latest SEC Form N-PORT filing, with weights normalized to the top 25; for each shared security we count the smaller of the two weights. Educational information, not investment advice.